BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial

Reuters12-04

Dec 4 (Reuters) - Absci Corp ABSI.O:

ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE™ TRIAL OF AI-DESIGNED ANTIBODY ABS-201™ FOR ANDROGENETIC ALOPECIA
ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026
ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026

Source text: ID:nGNXR58y

Further company coverage: ABSI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588388260?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588388260","market":"fut","top_or_hot":-1,"title":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial </title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Absci Corp <span>ABSI.O</span>:</p><ul><li><p>ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE™ TRIAL OF AI-DESIGNED ANTIBODY ABS-201™ FOR ANDROGENETIC ALOPECIA</p></li><li><p>ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026</p></li><li><p>ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026</p></li></ul><p>Source text: <span>ID:nGNXR58y</span></p><p>Further company coverage: <span>ABSI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 21:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial </title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Absci Corp <span>ABSI.O</span>:</p><ul><li><p>ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE™ TRIAL OF AI-DESIGNED ANTIBODY ABS-201™ FOR ANDROGENETIC ALOPECIA</p></li><li><p>ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026</p></li><li><p>ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026</p></li></ul><p>Source text: <span>ID:nGNXR58y</span></p><p>Further company coverage: <span>ABSI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABSI","symbol_name":"Absci Corporation.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:1","article_id":"2588388260","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588388260","pubTimestamp":1764854658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial Dec 4  - Absci Corp ABSI.O:ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE TRIAL OF AI-DESIGNED ANTIBODY ABS-201 FOR ANDROGENETIC ALOPECIAABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026Source text: ID:nGNXR58yFurther company coverage: ABSI.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABSI":"Absci Corporation.","BK4121":"生命科学工具和服务","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"简介-Absci宣布第一批参与者在1/2 A期头条试验中接受给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":0.9},"content_text":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial Dec 4 (Reuters) - Absci Corp ABSI.O:ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE™ TRIAL OF AI-DESIGNED ANTIBODY ABS-201™ FOR ANDROGENETIC ALOPECIAABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026Source text: ID:nGNXR58yFurther company coverage: ABSI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588388260","isCrawlerRequest":true}